Pharmaceutical Care Management Association (PCMA)’s Post

After decades of debate, the US Congress passed legislation authorizing Medicare to negotiate prescription drug prices. Be there for the first spotlight session of ISPOR 2024, when updates on the implementation and future steps regarding the first 10 drugs authorized for pricing review will be discussed. Hear viewpoints from the Center for Medicare and Medicaid Services, the pharmaceutical industry, and a drug pricing policy expert. Learn more and join us>> https://ow.ly/t1L950R9y6f #prescriptiondrugpricing #HEOR #ISPORAnnual

We have rebated $42.8 Billion dollars to your insurance entities last year. $13.4 to private insurance alone. How much of that have you seen in savings? That's $40 PER PERSON in the US, much more for the individual receiving the products likely over $500 per person. Healthcare overall needs to address this where you are more likely to get access to a therapy based on how much your insurance makes in reimbursement over a therapy that will work for you.

This report by Adam Fein offers valuable insights into the complexities of drug pricing and the gross-to-net bubble within the pharmaceutical industry. #pharma #drugpricing #healthcareeconomics

#PCMA along with #Caremark, #OptumRx, #expressscripts,#ESI, #CVS, #Optum have been stealing from the American people and this has been known for a very long time!!! The FTC and legislators previously sanctioned the PCMA and vertically-integrated PBMs greedy anti-competitive policies that have allowed this dire situation the American people live in today! Slow paced action or nearly inaction as we have seen by the FTC and legislators is just giving the greedy executives time to eliminate any competition and steal every last possible dollar from the American people, non-vertically integrated pharmacies and employers. #stopthesiphon PCMA and the Big 3 PBMs are ONLY in this for the money and they could care less about the patients and the wasteland they leave. The proof is in the pudding!!!

A new analysis demonstrates how the pharmaceutical industry’s profit margins are ten times greater than other sectors of the prescription drug supply chain. By the numbers: The pharmaceutical industry’s average annual net income margin was nearly 23%. The average margin for other sectors of the U.S. prescription drug supply chain – including distributors, retail pharmacies, PBMs and health plans – was just 2.3%.

How are prescription drug prices determined? In the world of healthcare, few topics spark as much debate and confusion as prescription drug pricing. Have you ever wondered why that little pill in your medicine cabinet costs so much? Let’s dive into the intricate world of pharmaceutical economics and uncover the factors that determine the price tags on our prescriptions. https://lnkd.in/e7XRxAyb

#gponline reports that the Royal Pharmaceutical Society (RPS) and RCGP have released a new toolkit to enhance the consistency, safety, and efficiency of repeat prescribing in GP practices and pharmacies. This is the first guidance of its kind in 20 years and aims to improve patient safety. #prescribing #generalpractice #pharmacy Find out more here: https://lnkd.in/eD4hw5mC

In the world of healthcare, few topics spark as much debate and confusion as prescription drug pricing. Have you ever wondered why that little pill in your medicine cabinet costs so much? Let’s dive into the intricate world of pharmaceutical economics and uncover the factors that determine the price tags on our prescriptions. https://lnkd.in/ek_6sUM4

In case anyone needs to be reminded that #drugpricing is complex, here is the Producer Price Index (#PPI) for Pharmaceutical Preparation Manufacturing (price received by pharmaceutical manufacturers) and Pharmacies and Drug Retailers (price received by retailers) along with the Consumer Price Index (#CPI) for Prescription Drugs (price paid by consumers out of pocket or by third party payers including insurance or government). (Data accessed 3/21/2024). What do you think? Bentley University Center for Health and Business Center for Integration of Science and Industry at Bentley University @Bentley University

Value based care (VBC) is being championed by many members of the pharmaceutical industry as a better way to provide care and services to patients. Matthew Hellinger, director of business consulting services at Kaufman Rossin, and Ian Goldberger, principal of transaction advisory services at Kaufman Rossin, discuss the hurdles that payers are facing and why they’re still pushing forward with VBC. Read on at Pharmaceutical Executive: https://okt.to/MCRWs7